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Background: Endoscopic submucosal dissection (ESD) is associated with a risk of 
bleeding. Bleeding is usually treated with diathermy, although this does carry a risk of 
mucosal thermal injury. Purastat is a topical hemostat that may be effective in 
controlling bleeding during ESD, thereby reducing the use of heat therapy. The aim of 
this study was to assess the reduction in heat therapy used in the interventional group 
(Purastat) compared with the control group. The secondary aims were to compare the 
procedure length, time for hemostasis, delayed bleeding rate, adverse events, and 
wound healing between the groups. 
Methods: This was a single-center randomized controlled trial of 101 patients 
undergoing ESD. Participants were randomized to a control group where diathermy was 
used to control bleeding or an interventional group where Purastat could be used. 
Follow-up endoscopy was performed at 4 weeks to assess wound healing. 
Results: There was a significant reduction in the use of heat therapy for intraprocedural 
hemostasis in the interventional group compared with controls (49.3% vs. 99.6%, 
P < 0.001). There were no significant differences in the procedure length, time for 
hemostasis, and delayed bleeding rate between the groups. Complete wound healing at 
4 weeks was noted in 48.8% of patients in the interventional group compared with 
25.0% of controls (P = 0.02). 
Conclusions: This study has demonstrated that Purastat is an effective hemostat that 
can reduce the need for heat therapy for bleeding during ESD. It may also have a role 






























































Endoscopic submucosal dissection (ESD) is an effective technique for removal of 
superficial gastrointestinal (GI) neoplasia. However, its uptake in the West has been 
hampered by concerns over a high complication rate and the lengthy learning curve. 
Intraprocedural bleeding (IPB) is a well recognized complication. The usual method of 
controlling IPB is with electrocautery that is applied through the tip of the knife or via 
hemostatic forceps [1,2]. Heat application may result in mucosal thermal injury that can 
lead to perforation. There is also a risk of post-ESD electrocoagulation syndrome 
(PEECS), which is associated with female patients, right-sided colonic lesions, and 
lesions of >4 cm in size [3]. 
Delayed bleeding is another risk associated with ESD, ranging from 1%–15% 
depending on lesion location, size, and anticoagulant use [4]. Prophylactic clipping 
following colonic endoscopic resection showed no benefit [5] and prophylactic 
coagulation of vessels over the resection base has only been shown to be effective in 
reducing delayed bleeding post-gastric ESD [6,7]. 
Recently, topical hemostats have emerged as alternative non-diathermic modalities to 
manage bleeding. These are supplied as opaque powders that can be sprayed over the 
bleeding point [8,9]. Purastat (3D-Matrix Europe Ltd., France) is a novel synthetic self-
assembling peptide that is licensed for use as a hemostat. Its unique transparent gel 
formulation forms an extracellular scaffold matrix when activated by the change in pH 
that occurs upon contact with blood. This matrix forms a stable mechanical barrier over 
the bleeding site thereby facilitating intrinsic in vivo hemostasis. 
Initial preclinical studies investigating this peptide have shown other benefits in 
addition to its hemostatic properties, including improved wound healing [10–14]. The 





























































33 vascular anastomotic sites in 25 patients [15]. It has also had favorable outcomes in 
nasal and cardiothoracic surgery [16,17]. Within endoscopy, its impact on delayed 
bleeding and wound healing following ESD has shown promise [18,19]. Only one small 
study of 12 gastric ESD patients has assessed its hemostatic efficacy – this showed it 
was effective in 92% of cases [20]. Purastat has been shown to be safe with no device-
related adverse events reported. However, a major limitation of the evidence available 
is that all the studies have lacked a control group for comparison. There are few data on 
the efficacy of Purastat in controlling IPB during endoscopic resection. However, if it 
could reduce the need for thermal hemostasis by controlling some of the bleeds 
encountered, it would improve the safety profile of ESD. 
The primary aim of the study was to assess the reduction in the use of heat for treatment 
of IPB during ESD when Purastat was used as a hemostat. The secondary aims were to 
compare the procedure length, time for hemostasis, delayed bleeding rate, adverse 
events, and wound healing in the interventional arm (Purastat) and control group. 
Methods
Study design
This study was a single-center randomized controlled clinical trial involving patients 
who were undergoing esophageal and colonic ESD procedures only. It was registered 
at http://www.clinicaltrials.gov (identifier: NCT02833558) and approved by the South 
Central Hampshire A research ethics committee (reference: 16/SC/0020). 
Study participants
Patients over 18 years of age scheduled for elective esophageal or colonic ESD for 
lesions of 2–5 cm were eligible for participation. Patients aged under 18 years, unable 





























































invasion, with an inherited or acquired coagulopathy likely to affect the risk of bleeding, 
or receiving an anticoagulant therapy, except for aspirin, that could not be stopped or 
bridged pre-procedure were excluded. All participants provided written informed 
consent for the ESD procedure and separate consent for participation in the study. 
Baseline demographic data were recorded. 
Randomization 
All patients recruited were randomized in a 1:1 fashion to either the control or 
interventional arms. Each participant was allocated a unique trial reference number and 
computer-generated randomization was carried out at the time of the ESD using a web-
based platform (https://www.sealedenvelope.com/). 
Blinding
This was a single-blind study where patients were not informed about their 
randomization allocation in order to increase reliability during follow-up. Owing to the 
differences in the interventions, it was not possible to blind the endoscopist performing 
ESD. 
Endoscopic technique and hemostatic intervention
Endoscopic submucosal dissection
All esophageal ESD procedures were done with the patient under general anesthetic 
with a planned overnight hospital stay. Colonic ESD procedures were performed as 
day-cases with the patient under conscious sedation. Uninterrupted single antiplatelet 
therapy with aspirin was permitted, while all other anticoagulants were discontinued 





























































One endoscopist (P.B.; lifetime experience of over 500 ESD procedures) performed all 
of the ESDs. Hybrid ESD was used in cases where significant submucosal fibrosis was 
anticipated and this was decided on the basis of lesion assessment at the time of the 
procedure prior to randomization. 
A standard lifting solution (500 mL Gelofusine + 1 mL 1:10000 adrenaline + 1 mL 1% 
indigo carmine) and the DualKnife or DualKnife J (Olympus Medical UK) were used 
for all procedures. An Erbe VIO 300D electrosurgical generator (Erbe Medical, 
Tübingen, Germany) was used for diathermy. Endocut I (effect 2, cut interval 3, cut 
duration 3) was used for mucosal incision followed by submucosal dissection on swift 
coagulation (effect 4, 50 W). The procedure length was measured in minutes as the time 
taken from the point of submucosal injection to the end of dissection. 
Hemostasis
The start and stop times for each episode of IPB were measured. The number of bleeds 
that stopped spontaneously without treatment was recorded. We used the definitions 
described in an earlier study to classify the bleeds into three grades (grade 1, mild 
oozing; grade 2, moderate non-spurting bleeding with visible vessel; grade 3, arterial 
spurting) [22]. 
Control arm
All patients allocated to the control group received electrocoagulation treatment for 
IPB. This was applied either via the endoscopic knife tip (swift coagulation mode; effect 
4, 50 W) or using a coagulation forceps (Coagrasper; Olympus Medical UK) on soft 






























































This was a pragmatic real-life study designed to incorporate the use of Purastat into the 
treatment of IPB in the interventional arm without increasing the complexity of the 
procedure. Purastat was used for grade 1 and 2 bleeds that were encountered outside 
the immediate vicinity of the tip of the knife or when the bleeding point was not easily 
accessible for diathermy (e.g. when the bleeding point was not clearly visible because 
of blood pooling, was situated in the deeper planes or at the edge of an incision where 
the bleeding vessel was not fully exposed, or where access to the lesion was unstable). 
Purastat was applied via a bespoke catheter inserted through the endoscope accessory 
channel (Fig. 1). The volume of Purastat used and the time to hemostasis was measured. 
If a bleed was not controlled by either Purastat or diathermy, the endoscopist was 
permitted to use other treatment modalities. 
Our previous experience with Purastat demonstrated that it worked best in grade 1 and 
2 bleeds, but not in grade 3 bleeds [22]. Therefore, the study protocol permitted the use 
of diathermy with the endoscopic knife tip (in grade 1 & 2 bleeds) if the bleeding point 
was clearly visible in the immediate vicinity of the knife and the Coagrasper in grade 3 
spurting bleeds where Purastat was not recommended. This strategy addressed any 
potential ethical dilemmas regarding the value of withdrawing the knife and inserting 
the catheter for Purastat delivery when the knife could achieve safe hemostasis.
Purastat was applied over the resection base at the end of all procedures in the 
interventional arm. No other treatment (prophylactic coagulation or clipping) was 
carried out in either group. The ease of application was recorded and any issues 
encountered (e.g. catheter blockage, interference with visibility or electrical 






























































All patients undergoing esophageal ESD received high dose proton pump inhibitor 
therapy (40 mg twice daily omeprazole or equivalent) for 8 weeks post-procedure. All 
patients returned approximately 4 weeks post-procedure for a repeat endoscopy to 
inspect the resection site. Complications or adverse events (delayed bleeding, 
perforation, unexpected hospital admissions) related to the ESD were recorded at this 
visit. Delayed bleeding was defined as overt hemorrhage occurring between 24 hours 
and 30 days post-procedure and requiring medical intervention 
(endoscopic/radiological/surgical management), with or without a blood transfusion. 
Immediate/early rebleeding was defined as overt hemorrhage occurring within the first 
24 hours post-procedure requiring intervention as above. 
All follow-up endoscopies were carried out by two experienced endoscopy fellows who 
were blinded to the patient’s randomization. We adapted the wound healing categories 
based on the Sakita and Fukutomi ulcer staging classification [23]. The categories used 
were healing ulceration, scarring, and complete healing (Fig. 2). 
Outcomes
The primary outcome was the mean reduction in intraprocedural heat therapy required 
when Purastat was used for hemostasis in ESD. 
Secondary outcomes measured were: total procedure length; time taken for hemostasis 
using Purastat compared with diathermy; proportion of patients with complete wound 
healing, scarring, and healing ulceration present at follow-up endoscopy; and 





























































Statistical methods and sample size calculation
An intention-to-treat analysis was performed. Baseline characteristics were compared 
using the independent t test for continuous variables (e.g. age and lesion size) and chi-
squared or Fisher's exact tests for categorical variables (e.g. sex, co-morbidities, anti-
thrombotic agents, en bloc resection, location, circumference, procedure type). Chi-
squared tests were also used to compare differences between the two arms in the 
primary end point and the secondary end points (delayed bleeding, adverse events, 
wound healing). P values obtained were two-sided and a P value of <0.05 was 
considered significant in all cases. Statistical analyses were carried out using SPSS 
version 24. 
The sample size calculation utilized the t test for two independent samples and was 
based on the primary outcome measure of reducing the number of episodes of IPB 
requiring heat for hemostasis. As there is a lack of data on hemostasis in ESD, the 
sample size calculation was based on assumptions derived from ESD expert experience. 
We assumed that hemostasis would be required on average 10 times per patient (with a 
standard deviation of 5). We hypothesized that Purastat would reduce the number of 
episodes of IPB requiring heat treatment by 30%. To detect this difference with 80% 
power (assuming a two-sided significance level of 5%), the study would require 45 
patients in each trial arm (90 patients in total). The recruitment target was increased by 
10% to 100 patients in order to account for study withdrawals. The sample size 
calculation was performed using R for Windows (version 3.5.3). 
Results
A total of 101 patients were recruited and randomized into the two groups from May 
2016 to April 2018. There were three patients who were withdrawn from the study: two 





























































proceed to ESD. There were five patients in the Purastat arm and two in the control arm 
who did not have any IPB. Therefore, the intention-to-treat analysis was performed on 
the remaining 91 patients (Fig. 3).
Baseline patient and procedural characteristics
There were no significant differences between the patient and lesion characteristics in 
the two groups (Table 1). Notably, this was a high risk study population with a high 
proportion of patients (50% in the Purastat group and 38% in the control group) having 
significant co-morbidities, such as cardiorespiratory conditions, diabetes, or previous 
cerebrovascular accident. About 40% of patients in each group had been on 
anticoagulant therapy which was stopped before the procedure. The study protocol 
permitted conversion from ESD to hybrid ESD (~10%) for reasons of technical 
difficulty or if time/patient tolerance proved a constraint. A similar proportion of 
patients (37% vs. 42%) underwent hybrid ESD, which is reflected in the low en bloc 
resection rates. 
Intraprocedural bleeding and primary outcome
There were 269 bleeds in 45 patients in the control group and 232 bleeds in 46 patients 
in the Purastat group. There was no significant difference in the proportion of bleeds 
requiring treatment in the two groups (95.3% vs. 97.4%) or the mean number of bleeds 
per patient (5.0 vs. 6.0) (Table 2). The majority of bleeds in both groups were grade 1 
and 2 bleeds. 
There was a 50% reduction in the number of episodes of IPB treated by diathermy in 
the interventional arm. Diathermy was used for 109/221 bleeds requiring treatment 
(49.3%) in the Purastat arm. In 100/109 bleeds, this was owing to the severity of the 





























































uses of diathermy were because of unsuccessful treatment with Purastat. There were 
112 bleeds that were treated with Purastat as a primary hemostat and nine that were 
treated following the application of diathermy. Purastat achieved complete hemostasis 
in 92.6% of these bleeds (112/121). 
Secondary outcomes 
The mean length of time for hemostasis using Purastat was similar compared with 
diathermy (70 vs. 78 seconds, P = 0.14) (Table 3). The total procedure time was also 
similar (74 vs. 81 minutes for the interventional and control arms, respectively). Only 
a small amount of Purastat was required (mean of 0.43 mL per bleed) for hemostasis 
and for prophylactic coverage of the resection base (mean of 2.03 mL per patient). 
Delayed bleeding and adverse events
There were two delayed bleeds in each arm (delayed bleeding rate 4.3% vs. 4.4%). All 
bleeds were managed endoscopically and no further episodes of rebleeding occurred 
post-endoscopy. There was one perforation in the interventional arm, which was 
unrelated to the application of Purastat and attributed to the lesion histology 
(submucosally invasive cancer). 
Technical feasibility
Purastat was rated as easy to apply with complete coverage of the resection base 
achieved in the interventional arm. It was reported to “interfere with visibility” in two 
patients: both had multiple sites of IPB within close proximity necessitating repeated 
applications of the gel in the same field of resection. 
Wound healing 
The median length of follow-up was 30 days in both groups. There was a significant 





























































group compared with controls (48.8% vs. 25.0%, P = 0.02) (Table 4). However, in a 
subgroup analysis according to location, no significant difference between the groups 
was noted in wound healing post-esophageal ESD (Table 5). This was in contrast to 
colorectal ESD, where a higher proportion of patients in the control group were noted 
to have ulceration over the resection site during follow-up endoscopy (56% vs. 17.6%, 
P = 0.01), indicative of incomplete wound healing. 
Discussion
Bleeding is a well recognized complication of ESD. IPB can prolong the procedure 
time, increase the risk or complexity of the ESD, and compromise the dissection planes. 
Delayed bleeding can lead to additional length of stay and increases the morbidity 
associated with the procedure. Thus far, conventional treatment of IPB has been carried 
out using diathermy, which can increase the risk of thermal injury. Our study 
investigated the use of a novel hemostat to tackle procedure-related bleeding, with the 
aim of reducing the amount of heat therapy required. 
We demonstrated that Purastat is a safe and viable hemostat for mild to moderate IPB 
during ESD and led to a significant reduction in the use of diathermy for hemostasis. 
This is the first randomized controlled study using this hemostat and both groups of 
patients were well matched in terms of their risk factors for bleeding. There was only 
limited conversion from ESD to hybrid ESD, which did not have a significant effect on 
the primary end point, given the ratio of conventional to hybrid procedures was similar 
in the two arms. 
There is limited literature available on the amount of energy needed to cause a full-
thickness perforation; however, it is widely accepted that any use of monopolar 





























































lead to PEECS. The incidence of PEECS and perforation in ESD is low and it would 
not have been pragmatic to power a trial with these end points, given the sample size 
required. Therefore, the number of “heat-treated bleeds” was used as a surrogate marker 
and was designated the primary outcome measure. Purastat may have a role in 
prevention of PEECS, although the existing literature has not assessed this. In this trial, 
there were no cases of PEECS in either arm, so we may not draw any firm conclusions 
from this. Nevertheless, a non-diathermic modality that allows the endoscopist to use 
heat judiciously will continue to make ESD safer. This is relevant as the ESD expertise 
in the West is currently not as good as in Japan and the risks are higher in the learning 
curve phase [24,25].  
This study also showed that the time taken to control IPB did not differ significantly 
with the modality of treatment used (just over a minute in both). The transparent nature 
of the gel made it possible for the endoscopist to accurately observe hemostasis as 
visibility was maintained after application. There were no instances of early rebleeding 
in either group.
The overall procedure time was also not prolonged in the interventional arm. Purastat 
was not used for every bleed encountered as, in some bleeds, it was more pragmatic not 
to exchange the endoscopic knife for the Purastat catheter, given the location of the 
bleed and access. We felt that this model of tailoring the use of Purastat depending on 
the type of bleed was the most practical way of using it and anticipate that future users 
will adopt a similar strategy. 
Our study also showed that only a small amount of Purastat was needed. It was feasible, 
in many cases, for just a single 3-mL vial of hemostat to be used per ESD. We reported 
on the technical aspects of gel application and found that there were no instances of 





























































were no clinically perceptible differences in the conduction of current in this field. In 
two cases, it was found to interfere with visibility, although it was possible to remove 
the gel by vigorous flushing. 
The overall delayed bleeding rate in this study was low (4%) and no difference was 
noted between the groups. It is encouraging to note that there was no increase in delayed 
bleeding in the interventional arm, which may permit us to infer that the hemostatic 
efficacy of Purastat is sustained. In a previous study where Purastat was used 
prophylactically following gastric ESD, the delayed bleeding rate was noted to be 2.2% 
(no direct control group but this figure is lower than the average rate quoted in the 
literature) [18]. 
Purastat may have beneficial effects on wound healing as noted in preclinical animal 
studies [10]. The extracellular scaffold matrix promotes cell regeneration and 
connective tissue repair, which may accelerate wound healing. It has been trialed for 
use in the prevention of esophageal strictures after endoscopic resection in porcine 
models, where the stricture rate in the interventional group was lower than the control 
group (40% vs. 100%, P = 0.2) [26]. Only one other human clinical trial investigating 
the wound healing effects of Purastat has been carried out, which demonstrated that 
96% of cases reached the healing stage of post-gastric ESD ulceration after 1 week and 
98% reached the scarring stage by 8 weeks [18]. In our study, almost 75% of the 
patients followed up in the Purastat group achieved either complete wound healing or 
scarring compared with 54% in the control group at 4 weeks. However, we noted that 
there was no difference in the stages of wound healing in the esophageal ESD patients. 
This may be because of the high dose proton pump inhibitor therapy and the timing of 





























































ESD, 82% of patients in the Purastat group achieved complete healing or scarring 
compared with 44% of controls. 
There were several limitations to this study. Firstly, we did not include patients 
undergoing gastric ESD (where the incidence of bleeding is higher), as the prevalence 
of early gastric cancer in our population is low. However, Purastat may have a role to 
play in reducing delayed bleeding in this group as two previous studies using Purastat 
prophylactically post-gastric ESD have shown low delayed bleeding rates (0–2%), 
although both lacked a control group [18,19]. A matched control study assessing the 
hemostatic effects of Purastat following gastric endoscopic resection would increase 
our understanding of its properties. 
Secondly, given the paucity of data on IPB during ESD, we assumed that esophageal 
and colonic ESD would have a similar incidence of bleeding and therefore did not 
power the study to stratify recruitment and randomization according to lesion location. 
Thirdly, as this was a pragmatic clinical trial designed to fit in with standard clinical 
practice, we were not able to carry out additional follow-up procedures at weeks 1 and 
2 post-ESD. This may have affected accurate assessment of the transition between the 
stages of wound healing. It was also difficult to assess the impact of Purastat on the 
incidence of PEECS, given the lack of data available and small sample size. We 
acknowledge that Purastat will add to the cost of the procedure, but this study did not 
assess its cost-effectiveness and impact on delayed bleeding as the focus was to 
understand the basic principles of its efficacy and safety. 
Despite the limitations, this study is the first randomized controlled trial to investigate 
a novel hemostat for control of IPB during ESD. The primary end point of the trial was 
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Fig. 1 Endoscopic views showing the application of Purastat for 
intraprocedural bleeding.
Fig. 2 The stages of wound healing of the resection base following 
endoscopic submucosal dissection were categorized as: a  healing 
ulceration; b  scarring; c  complete healing.





































































Age, mean (SD), years 68.6 (10.6) 71.5 (11.2) 0.22
Lesion size, mean (SD), mm 33.7 (12.1) 36.6 (13.6) 0.29
Sex, male : female, n 33 : 13 27 : 18 0.27
Co-morbidities present, n (%) 23 (50.0%) 17 (37.8%) 0.24
  Cardiovascular disease 20 (43.5%) 15 (33.3%) 0.39
  Ischemic heart disease   6 (13.0%)   7 (15.6%) 0.77 
  Hypertension   7 (15.2%)   5 (11.1%) 0.76
  Atrial fibrillation   6 (13.0%)   4 (8.9%) 0.74
  Valvular abnormalities   2 (4.3%)   0 0.50
  Peripheral vascular disease   2 (4.3%)   2 (4.4%) >0.99
  Diabetes mellitus   2 (4.3%)   3 (6.7%) 0.68
  Asthma/COPD   1 (2.2%)   1 (2.2%) >0.99
  Cerebrovascular accident/TIA   2 (4.3%)   2 (4.4%) >0.99
  Chronic liver disease   0   0 >0.99





























































  Warfarin   5 (10.9%)   3 (6.7%) 0.71
  Novel oral anticoagulant   1 (2.2%)   3 (6.7%) 0.36
  Aspirin   7 (15.2%)   6 (13.3%) >0.99
  Clopidogrel   6 (13.0%)   6 (13.3%) >0.99
En bloc resection rate, n (%) 35 (76.1%) 31 (68.9%) 0.44
Esophageal 28 (60.9%) 20 (44.4%)Location, n (%) 
Colorectal 18 (39.1%) 25 (55.6%)
0.12
<50% 32 (69.6%) 26 (57.8%)Circumference, 
n (%) >50% 14 (30.4%) 19 (42.2%)
0.24
ESD 29 (63.0%) 26 (57.8%)Procedure 
type, n (%) Hybrid ESD 17 (37.0%) 19 (42.2%)
0.61
SD, standard deviation; COPD, chronic obstructive pulmonary disease; TIA, 





























































Table 2 Comparison of intraprocedural bleeding (IPB) and hemostat use 








Total episodes of IPB, n 232 269 N/A
Episodes of IPB that stopped 
spontaneously, n (%) 
11 (4.7%) 7 (2.6%) 0.20
Episodes of IPB that required 
hemostasis, n (%)
221 (95.3%) 262 (97.4%) 0.20
Grade 1 105 (47.5%) 151 (57.6%) 0.03
Grade 2 102 (46.2%) 101 (38.5%) 0.09
Severity of 
bleeding, n (%)
Grade 3   14 (6.3%)   10 (3.8%) 0.21
Episodes of IPB treated with 
heat, n (%)*
109 (49.3%) 261 (99.6%)† 0.001
Episodes of IPB treated with 
Purastat, n (%)‡
121 (54.8%) 0 N/A
Successful hemostasis 
achieved with Purastat, n (%)






























































* Includes nine bleeds treated with heat following unsuccessful hemostasis
with Purastat.
† One bleed required the use of endoscopic clips for safe hemostasis.






































































Procedure length, mean (SD), 
minutes
74.2 (48.7) 80.7 (56.6) 0.56
Time for hemostasis per bleed, 
mean (SD), seconds
70.0 (76.1) 77.6 (274.2) 0.14
Immediate/early rebleeding, n 0 0





































































Table 4 Comparison of wound healing between the two groups.







Complete healing, n (%) 21 (48.8%) 11 (25.0%) 0.02
Scarring, n (%) 11 (25.6%) 13 (29.5%) 0.69





























































Table 5 Subgroup analysis of wound healing according to lesion location.












14 (53.8%) 7 (36.8%) 0.26 7 (41.2%) 4 (16.0%) 0.07
Scarring 4 (15.4%) 6 (31.6%) 0.20 7 (41.2%) 7 (28.0%) 0.38
Healing 
ulceration
8 (30.8%) 6 (31.6%) 0.96 3 (17.6%) 14 (56.0%) 0.01
In brief 
A novel self-assembling peptide was shown in this single-center randomized controlled 
trial, involving 101 patients, to reduce the need for thermal therapy for intraprocedural 
hemostasis during esophageal or colonic ESD, with no difference in procedural time, 
time for hemostasis, or delayed bleeding rate. Further studies are needed to investigate 





























































Figure 1: Application of Purastat® for intraprocedural bleeding 





























































Figure 2: Stages of Wound Healing of ESD Resection Base
(a) Healing Ulceration; (b) Scarring; (c) Complete Healing



































































Excluded (n = 5):
 No bleeds (n = 5)
Excluded (n = 5):
No bleeds (n = 2)
Aborted ESD (n = 2)





Follow-up endoscopy (n = 43)
Underwent esophagectomy (n = 2) 
Declined follow-up (n = 1)
Follow-up endoscopy (n = 44)
Underwent esophagectomy (n = 1)
Randomized to control
(n = 50)
Excluded (n = 45): 
Not meeting inclusion criteria (n = 42)
Declined consent (n = 3)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
